Sei Investments Co. Boosts Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Sei Investments Co. boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 6.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 673,868 shares of the medical research company’s stock after purchasing an additional 38,827 shares during the period. Sei Investments Co.’s holdings in Charles River Laboratories International were worth $124,394,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. American Century Companies Inc. boosted its stake in shares of Charles River Laboratories International by 5.6% in the fourth quarter. American Century Companies Inc. now owns 2,984 shares of the medical research company’s stock valued at $551,000 after buying an additional 157 shares in the last quarter. Quantbot Technologies LP boosted its position in shares of Charles River Laboratories International by 13.8% during the 4th quarter. Quantbot Technologies LP now owns 9,300 shares of the medical research company’s stock worth $1,717,000 after purchasing an additional 1,131 shares in the last quarter. Royal London Asset Management Ltd. grew its stake in shares of Charles River Laboratories International by 6.4% during the 4th quarter. Royal London Asset Management Ltd. now owns 16,425 shares of the medical research company’s stock worth $3,032,000 after purchasing an additional 991 shares during the period. Cibc World Markets Corp lifted its stake in shares of Charles River Laboratories International by 16.1% in the fourth quarter. Cibc World Markets Corp now owns 8,086 shares of the medical research company’s stock valued at $1,493,000 after purchasing an additional 1,124 shares during the period. Finally, Hilton Capital Management LLC boosted its holdings in Charles River Laboratories International by 5.0% during the fourth quarter. Hilton Capital Management LLC now owns 8,038 shares of the medical research company’s stock worth $1,484,000 after buying an additional 380 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

CRL stock opened at $167.29 on Friday. The stock has a market capitalization of $8.55 billion, a price-to-earnings ratio of 1,115.26, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The stock’s fifty day simple moving average is $166.11 and its 200-day simple moving average is $183.71. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $273.57. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. During the same quarter in the previous year, the business earned $2.46 EPS. The firm’s revenue was down 1.1% on a year-over-year basis. Equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of research analyst reports. The Goldman Sachs Group cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their target price for the company from $190.00 to $170.00 in a report on Friday. UBS Group reaffirmed a “neutral” rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target for the company in a research note on Monday, March 3rd. Finally, Robert W. Baird lowered their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $189.77.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).